New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
16:28 EDTINO, VRX, EBAY, EHTH, AGN, RCPT, COUP, FBOn The Fly: Closing Wrap
Stocks on Wall Street began the day slightly below the flat line and remained there for most of the session, before a late move higher allowed the Dow to run its recent winning streak to another day, though just barely. Economic reports from at home and abroad, which included wholesale trade data in the U.S. and inflation data from China, had little effect on the market, which seemed content to spend the session drifting. The Dow and S&P 500 stand just short of major round-number milestones, but both will have to wait at least another day to see if they can be reached. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 1.1% in April, with sales up 1.3%, which were both better than forecast. The JOLTS report showed job openings climbed 289K to 4.46M in April. In China, official data showed an index of consumer prices rose 2.5% year-on-year in May, while China's producer price index contracted 1.4% during the month. COMPANY NEWS: Shares of eBay (EBAY) closed down $1.33, or 2.68%, to $48.25 after the company announced last night that PayPal President David Marcus is leaving the company to lead Facebook’s (FB) messaging products. Facebook shares reacted positively to the executive hiring, rising $2.89, or 4.6%, to $65.77... Allergan (AGN) once again rejected Valeant (VRX), saying that the higher takeover bid it made in concert with Bill Ackman's hedge fund Pershing Square still "substantially undervalues the company [and] creates significant risks and uncertainties for the stockholders of Allergan." Further, Allergan said its board has "serious concerns" about the large stock component of the proposal and that the latest Valeant offer does not warrant talks between the companies. Following the latest reproach, BMO Capital said it believes the fight between the two is still in the "early innings" and could last well into 2015. Shares of Allergan slipped $1.06, or 0.65%, to $163.09, while Valeant fell $1.08, or 0.85%, to $125.55. MAJOR MOVERS: Among the notable gainers was hepatitis C treatment maker Achillion (ACHN), which surged $3.54, or 83.29%, to $7.79 after the company announced today that it had received favorable news from the FDA about resuming certain clinical trials. Achillion's advance comes on top of its 47% move higher yesterday after Merck (MRK) announced that it would acquire another company in the HCV drug space at a significant premium. Also higher was Receptos (RCPT), which jumped $10.74, or 36.78%, to $39.94 after the company reported phase 2 data for its SIPI modulator that firms Leerink and BMO Capital both viewed positively. Among the noteworthy losers was Inovio Pharmaceuticals (INO), which fell $1.44, or 13.36%, to $9.34 after TheStreet's Adam Feuerstein speculated that the company already has data in hand for its phase II study of its vaccine for cervical pre-cancerous lesions and warned of "red flags" related to the company's CEO "walking back expectations" ahead of a potential disclosure that the trial was not a success. Also lower were shares of eHealth (EHTH), which fell $5.09, or 13.05%, to $33.91 after Jefferies downgraded the stock to Hold and lowered its price target for shares to $40 from $62, citing less confidence in the company's Exchange opportunity following management comments at the firm's conference. Another stock moving lower following a downgrade was Coupons.com (COUP), which dropped $2.95, or 10.6%, to $24.88 after Goldman downgraded the shares to Sell from Neutral. INDEXES: The Dow was up 2.82, or 0.02%, to 16,945.92, the Nasdaq was up 1.75, or 0.04%, to 4,338.00, and the S&P 500 was down 0.48, or 0.02%, to 1,950.79.
News For EBAY;FB;AGN;VRX;COUP;EHTH;INO;RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 15, 2015
06:42 EDTRCPTReceptos downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:28 EDTRCPTCelgene price target raised to $175 from $160 at Deutsche Bank
Subscribe for More Information
05:59 EDTRCPTPiper views Receptos buyout as good for Arena
Piper Jaffray analyst Edward Tenthoff views Celgene's (CELG) acquisition of Receptos (RCPT) as good for Arena Pharmaceuticals (ARNA). Tenthoff views Arena as a "derivative call" on the deal with the company's APD334 already showing dose-dependent decreases in circulating lymphocyte counts. Arena will also initiate Phase II studies in ulcerative colitis and Crohn's disease this year, the analyst points out. Receptos' ozanimod is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. Tenthoff reiterates an Overweight rating on Arena with a $7.50 price target. The company has a market capitalization around $1B and closed yesterday up 8c to $4.47
05:52 EDTRCPTReceptos deal 'another good move' for Celgene, says Piper Jaffray
Subscribe for More Information
July 14, 2015
19:05 EDTRCPTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CSX (CSX), up 3.5%. ALSO HIGHER: Receptos (RCPT), up 10.2% following deal to be acquired by Celgene (CELG)... Celgene is up 5.8% after announcing acquisition of Receptos... Celsion (CLSN), up 8.8% after being initiated with a Buy at BTIG... Aratana Therapeutics (PETX), up 10% after results of pivotal study of AT-003. DOWN AFTER EARNINGS: Peregrine (PPHM), down 3%... Yum! Brands (YUM), down marginally. ALSO LOWER: Allegheny Technologies (ATI), down 9.3% after providing second quarter EPS guidance... Mead Johnson (MJN), down 4.8% after reducing fiscal 2015 EPS guidance.
18:18 EDTRCPTCelgene sees Receptos team staying on board following acquisition
Subscribe for More Information
18:08 EDTRCPTImmuno-oncolgy stocks advance after Receptos acquired by Celgene
Subscribe for More Information
18:07 EDTRCPTCelgene sees Receptos deal accretive in 2019
18:06 EDTRCPTCelgene downplays regulatory concerns in Receptos deal, sees closing in Q3
Subscribe for More Information
17:52 EDTEBAYS&P announces changes to the S&P 500, 400, 600, and 100 indices
Subscribe for More Information
17:31 EDTRCPTReceptos up about 10% following deal to be acquired by Celgene
Subscribe for More Information
17:30 EDTRCPTCelgene up about 5% after announcing acquisition of Receptos
Subscribe for More Information
17:25 EDTEBAYPayPal to replace eBay in s&P 100 as of 7/17 close
17:02 EDTRCPTCelgene to acquire Receptos for $232 per share in cash, or about $7.2B
Subscribe for More Information
16:59 EDTRCPTCelgene to acquire Receptos for $232 per share in cash
16:01 EDTFBOptions Update; July 14, 2015
iPath S&P 500 VIX Short-Term Futures down 15c to 17.76 Option volume leaders: AAPL FB BAC T AMZN BABA INTC JPM LVS AAL CHK MSFT NFLX TSLA TWTR MPC
09:35 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB BAC T AMZN BABA INTC JPM LVS AAL CHK MSFT
09:32 EDTEBAYeBay mentioned positively following Q2 checks at ITG Research
Subscribe for More Information
06:46 EDTFBFacebook Messenger to add 'Moneypenny' feature, The Information reports
Subscribe for More Information
06:14 EDTFBFacebook's Instagram has 14M monthly active users in U.K., Business Insider says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use